SymBio Pharmaceuticals Limited
SYMQY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.55M
Close$
$-0.14
150.4% downside
Current Fair Value
150.4% downsideOvervalued by 150.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $23.55 Million |
|---|---|
| Enterprise Value | $-120,175,222.00 |
| Earnings per Share | $-99.73 |
| Beta | 0.53 |
| Outstanding Shares | 83,969,857 |
Return
| Return on Equity | 1062.30% |
|---|---|
| Return on Assets | -324.60% |
| Return on Invested Capital | 1068.15% |
Valuation & Multiples
| P/E Ratio | -0.48 |
|---|---|
| PEG | -13.67 |
| Price to Sales | 0.02 |
| Price to Book Ratio | -0.04 |
| Enterprise Value to Revenue | 2.14 |
| Enterprise Value to EBIT | -0.37 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | -1.43 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About SymBio Pharmaceuticals Limited
91 employees
CEO: Fuminori Yoshida
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, ...